Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in A
Go back to Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in A| Merck & Co. (NYSE: MRK) | Delayed: 150.91 +1.41 (0.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $149.50 | 52 Week High | $65.46 | |||
| Open | $148.69 | 52 Week Low | $47.97 | |||
| Day High | $153.57 | P/E | 102.66 | |||
| Day Low | $148.04 | EPS | $1.47 | |||
| Volume | 11,172,873 | |||||
